The Bridge You Don’t Notice

Feeling like yourself again is a good reason to review treatment. It does not, by itself, show that treatment has become unnecessary. Maintenance treatment aims to reduce the chance of another episode while helping you live a life that feels like yours. The right question is not simply whether you can stop. It is what each medicine is doing now, what it costs you, and how to review the plan together.

That review may support keeping a medicine, changing it, or simplifying a combination. A drug added during a crisis does not by itself belong in your plan forever. At the same time, stopping can remove useful protection. Maintenance guidance supports an ongoing, shared review of both benefit and burden.1

Key takeaways

• Feeling well is a reason to review the plan with your prescriber, not proof by itself that a medicine is finished.
• Stopping studies compared groups of people who had already improved on a medicine; they cannot forecast what one person will experience after a change.
• Bring one clear benefit, one concrete burden, and what you actually take, and agree who checks in and what would trigger an earlier review.

Zoom

Well is an outcome worth understanding

Remission means that symptoms have fallen below the level of a full episode. Recovery usually means that improvement has lasted and everyday life is coming back, though research uses different definitions. You may be sleeping again but still need time to rebuild work, trust, or confidence. Maintenance is the care used to help sustain wellness and reduce future episodes.

Think of a bridge that makes an ordinary trip possible. On a calm day, its upkeep is easy to forget because the trip feels uneventful. Treatment can also become less visible when it works. The analogy stops there: you are not a failing structure, and a maintenance plan can be revised. It must serve your life.

It helps to ask what happened before each prescription. Was it added for mania, depression, severe insomnia, or distress during a hospital stay? Has that need changed? A medicine called a “mood stabilizer” does not necessarily prevent both poles equally. The reason for using it matters more than the broad label.

What stopping studies can tell us

Across randomized trials, people assigned to continue a useful maintenance medicine generally had fewer recurrences than people assigned to stop it. That finding supports prevention. It cannot predict what will happen to one person after a change. The studies included different medicines, follow-up periods, and ways of stopping. Many enrolled people who had already improved on the medicine and could tolerate it. Kishi and colleagues reviewed these comparisons.2

That design answers a focused question: what happens when a treatment that has helped selected participants is continued or withdrawn? It gives less direct guidance for someone whose medicine never helped, who has serious side effects, or whose diagnosis needs review. A published correction affects figures in that review, so this article does not turn its pooled numbers into a personal forecast.

There is also evidence that some acute combinations deserve a later review. In one trial, adults recently well after mania continued lithium or valproate while the added antipsychotic was reviewed at different times. Continuing the add-on initially helped, but the longer comparison was less clear and weight burden mattered. This was a specific study, not a rule to stop every add-on at a set date. The original trial explains why prevention and simplification can both belong in the conversation.5

A change can be followed by several different things

Withdrawal symptoms are effects that can occur as the body adjusts after reducing or stopping a drug. Loss of protection means the medicine is no longer providing its previous benefit. A recurrence is a new illness episode. These can overlap, and the timing alone may not sort them out.

Researchers sometimes use “rebound” to mean an unusually high or early return of symptoms after stopping. The word does not always mean the same thing across studies. It should not become a catchall explanation for every difficult day after a change. Nor does an early episode prove that the same dose must remain unchanged forever.

Lithium has some of the clearest evidence that the pace of stopping matters. Older prospective work and a newer observational study found earlier recurrence after stopping more quickly. The participants were not randomly assigned to all the conditions that led them to stop. Medical problems and illness history could also affect their outcomes. Faedda’s study and the later analysis support caution, not a reader-run schedule.34

You cannot safely transfer a lithium finding to every antipsychotic, anticonvulsant, antidepressant, or combination. A gradual change may reduce some risks, but it does not make recurrence impossible. Your prescriber needs to choose the pace, observations, and follow-up for the actual medicine and your history.

The costs of treatment belong in the record

“It works” can be true while “I cannot keep living with this side effect” is also true. Sedation may make driving or early shifts hard. Slowed thinking may affect a job. Weight changes, sexual effects, tremor, and feeling emotionally dulled can alter daily life. Pregnancy plans, kidney concerns, and other health changes may create new priorities.

Cost and access count too. A refill problem is not the same as deciding treatment has no value. Neither is missing doses because a pharmacy is far away or a work shift makes appointments difficult. Stigma may make it hard to take medicine around others. These are facts the team needs, not evidence of a character flaw.

A study of why people stopped lithium found many different reasons for stopping, including adverse effects and personal preferences. Such records cannot tell us which choice is right for you. They do show why asking only “Are you taking it?” misses much of the story. Öhlund and colleagues examined those reasons.6

Try to name the burden in terms another person can understand. “I feel tired” is useful. “I fall asleep before I can help my child with homework” adds a goal. You do not need to make the concern sound severe enough to earn a review. You also do not need to minimize a serious reaction to seem cooperative.

What a shared review should cover

Your past course helps frame the choice. The team may review the diagnosis, the severity of past episodes, and whether depression or mania has caused more difficulty. Previous benefit, past changes, hospital care, psychosis, and recurrence after stopping all matter. None should be used as a threat.

The present matters as well. A planned move, night work, current sleep loss, alcohol or cannabis use, and trouble getting follow-up may change what support is needed. A chosen supporter can help describe changes if you agree. You can also ask to discuss sensitive concerns privately.

There is no single correct length of maintenance treatment for every person. Some people have strong reasons for a long-term plan. Others need careful reassessment of one part of a combination. A review can be successful even when the immediate decision is to keep treatment and address a burden first.

A conversation that can start honestly

Hypothetical conversation

“I want to talk about coming off this because I feel slowed down at work. I have already missed several doses. I was worried you would be angry.”

“Thank you for telling me. Which medicine and which doses did you miss? What has changed in your sleep, mood, or energy? Let’s check what needs attention today, then look at the benefit, the burden, and our options.”

That response leaves room for both safety and choice. You can ask the clinician to explain why they favor one option and what would make them reconsider it. If you disagree, ask for the concern to be recorded and for another review. You do not have to hide your experience to remain part of care.

It can help to bring the pill bottles or an accurate list. Include medicines from other clinicians and products bought without a prescription. If you do not remember every missed dose, say what you know and what you are unsure about. An honest estimate is more useful than a tidy but inaccurate history.

If there has already been a gap

Contact the prescribing team or pharmacist promptly when you have run out, stopped, or missed enough treatment to be unsure what to do. Say when you last took each medicine and whether symptoms have changed. Ask for advice for that drug and a route to an authorized refill. Do not double doses to make up a gap.

Do not assume the old dose is safe to restart. Lamotrigine needs particular care after an interruption because restart decisions depend on how long it has been, other medicines, and any rash history. Its prescribing information also says it should ordinarily be stopped at the first sign of rash unless the rash is clearly unrelated. A new rash needs urgent clinical advice; blistering, mouth sores, fever, or severe illness need emergency assessment. Current lamotrigine instructions take priority over a general message about planned changes.8

You may fear that restarting lithium will never work again. The available evidence is mixed and limited; many people regain benefit, while some reports raise concern about reduced response. That is a reason to review the history, not to assume treatment is hopeless or to restart on your own. A 2024 review describes those limits.7

Ask for an answer you can use

You can ask to focus on one concern at a time. If tiredness is the main problem, begin there. If fear about long-term health is the main problem, say that. A list of ten worries can be hard to discuss in a short visit, but you do not need to abandon the rest. Ask which concern needs action first and when the others will be heard.

At the end, try saying the plan back in your own words. “My next step is to call about the refill, and we will review the side effect at this visit.” If the clinician hears something different from what they meant, that is a chance to make the plan clearer. Ask for a written copy you can read later.

You may want a second opinion if the reason for treatment remains unclear. Bring the full history and medicine list so the new clinician can review the same facts. Seeking another view should not require a secret change or a break in access to care.

Write down what the change plan means

A clinician-supervised plan should state the reason for review, the alternatives discussed, and which medicine is being considered. Ask who will check in, how to reach them, and what changes should trigger earlier reassessment. The plan should also cover weekends, travel, and problems obtaining the prescription.

Agree on a few observations that fit your life. Sleep need, unusual drive, hopelessness, spending, or a task that usually becomes difficult may be useful. These observations can draw on your personal relapse signature. They do not diagnose an episode or prove that a change is safe.

Supporters should know what help you want and what information you agree to share. A request to notice changes is not permission to inspect your phone, count pills secretly, or control decisions. If a supporter cannot be involved safely, the team can plan other ways to maintain contact.

When the review cannot wait

Routine review: bring manageable side effects, questions about duration, or a wish to simplify to the prescribing visit. Ask sooner if the appointment is too far away to address a growing problem.

Prompt assessment: contact the team today for a major sleep or energy change, new severe restlessness, worsening depression, unsafe impulsivity, or a treatment gap with emerging symptoms. Do not wait for a full episode or a fixed number of sleepless nights.

Immediate danger or suspected serious reaction: seek urgent medical help. If lithium toxicity is suspected, stop/withhold lithium and obtain urgent assessment; do not wait for the next lab or try fluids alone. Severe confusion, collapse, seizure, breathing difficulty, or immediate danger calls for 911. The lithium Medication Guide gives drug-specific warning signs.9 For crisis support when you are unsure what to do, call or text 988 (the Suicide & Crisis Lifeline) or use your local crisis route.10

This week, write the main reason you want your treatment reviewed, add any changes already made, and bring that note to the prescriber before making a planned change.

Frequently asked questions

Do I need medication forever?

There is no single answer for everyone. Your past episodes, response, harms, and current circumstances affect the long-term plan. Some people benefit from ongoing treatment over many years. That does not make every medicine in a past crisis combination permanent. Ask what each one is intended to prevent and when that decision will be reviewed.

Is feeling well evidence that I no longer need it?

Feeling well is evidence that your current situation deserves attention and protection. It cannot show which part of recovery came from medication, time, support, or other care. Maintenance studies suggest useful protection can persist when symptoms are quiet. Review both wellness and burdens with the team before treating the absence of symptoms as a reason to stop.

Is dependence the same as maintenance treatment?

No. Taking a medicine to prevent illness is different from addiction, which involves a problematic pattern such as loss of control and continued use despite harm. Some medicines can still cause withdrawal symptoms after changes. The terms should not replace a drug-specific explanation. Ask what stopping might involve for your actual prescription.

Is tapering risk-free?

No. A gradual, supervised change may address some risks, but it cannot promise that symptoms will not return. The plan must fit the medicine, illness history, and access to assessment. Ask what the team will watch for and how the plan would change if your health worsens. Do not borrow another person’s schedule.

What if I already stopped?

Tell the prescriber or pharmacist when you last took each medicine and how you feel now. Ask for drug-specific advice before restarting, especially with lamotrigine. Do not double missed doses. If you have serious symptoms or a suspected harmful reaction, seek urgent assessment rather than waiting for a routine appointment or trying to correct the gap alone.

Can we simplify a combination?

Sometimes that is a useful goal. The review should identify why each medicine was started, what still helps, and which burdens matter most. It may be possible to revise one part while preserving needed protection. Whether to do so, and how, requires an individual plan with follow-up, not a general rule about the number of medicines.

This article is for education, not personal medical advice. Do not start, stop, restart, or change a medication without the clinician who manages it. Every PubMed citation, crisis number, and internal link in this article was verified against its primary source on September 8, 2026. Guidelines, drug labels, and public-health data change; confirm current status before acting on anything here.

Related reading on NP FADY

• “Retrofit in Calm Weather”: Building Your Relapse Signature
• Mood Stabilizers Demystified: Lithium, Lamictal, and Beyond
• The Level Is a Conversation, Not a Grade
• What Actually Lifts the Low Side
• The Work Between Appointments
• “The Shout and the Hum”: Bipolar I vs. Bipolar II

References

1. Yatham LN, et al. CANMAT and ISBD 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders. 2018;20:97–170. Full guideline.

2. Kishi T, et al. Recurrence rates in stable bipolar disorder patients after drug discontinuation versus drug maintenance: a systematic review and meta-analysis. Psychological Medicine. 2021;51:2721–2729. doi:10.1017/S0033291720003505. Original abstract. 2021 corrigendum.

3. Faedda GL, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Archives of General Psychiatry. 1993;50:448–455. doi:10.1001/archpsyc.1993.01820180046005. Original report.

4. Baldessarini RJ, et al. Risk factors for early recurrence after discontinuing lithium in bipolar disorder. Bipolar Disorders. 2022;24:720–725. doi:10.1111/bdi.13206. Original report.

5. Yatham LN, et al. Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode. Molecular Psychiatry. 2016;21:1050–1056. doi:10.1038/mp.2015.158. Original trial.

6. Öhlund L, et al. Reasons for lithium discontinuation in men and women with bipolar disorder: a retrospective cohort study. BMC Psychiatry. 2018;18:37. doi:10.1186/s12888-018-1622-1. Corrected article.

7. Kupka R, et al. Lithium-discontinuation-induced treatment refractoriness revisited. International Journal of Bipolar Disorders. 2024;12:17. doi:10.1186/s40345-024-00339-6. Full review.

8. GSK. LAMICTAL prescribing information and Medication Guide. Revised October 2025. Current product information.

9. PAI Pharma. Lithium oral solution Medication Guide. Revised January 2025. U.S. Medication Guide.

10. Suicide & Crisis Lifeline. Get help. Accessed September 8, 2026. Official support route.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.